Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Non-Current Assets (2019 - 2025)

IDEAYA Biosciences (IDYA) has disclosed Non-Current Assets for 7 consecutive years, with $442.6 million as the latest value for Q4 2025.

  • Quarterly Non-Current Assets rose 1.89% to $442.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.6 billion through Dec 2025, up 25.41% year-over-year, with the annual reading at $442.6 million for FY2025, 1.89% up from the prior year.
  • Non-Current Assets hit $442.6 million in Q4 2025 for IDEAYA Biosciences, up from $382.5 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $442.6 million in Q4 2025 to a low of $17.5 million in Q3 2022.
  • Historically, Non-Current Assets has averaged $178.7 million across 5 years, with a median of $123.5 million in 2021.
  • Biggest five-year swings in Non-Current Assets: soared 1248.83% in 2021 and later crashed 86.61% in 2022.
  • Year by year, Non-Current Assets stood at $130.4 million in 2021, then plummeted by 86.56% to $17.5 million in 2022, then soared by 566.19% to $116.7 million in 2023, then surged by 272.27% to $434.4 million in 2024, then rose by 1.89% to $442.6 million in 2025.
  • Business Quant data shows Non-Current Assets for IDYA at $442.6 million in Q4 2025, $382.5 million in Q3 2025, and $355.7 million in Q2 2025.